Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus

Neuro-Oncology

Volumn 16, Issue 8, 2014, Pages 1057-1066

  Antoszczyk, Slawomir ^a   Spyra, Melanie ^b   Mautner, Victor Felix ^b   Kurtz, Andreas ^c,d   Stemmer Rachamimov, Anat O ^a   Martuza, Robert L ^a   Rabkin, Samuel D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Seoul National University   (South Korea)

Author keywords

Cancer stem cells; HSV; IL 12; MPNST; Neurofibromatosis; Sciatic nerve; Virotherapy

Indexed keywords

HSV G47; INTERLEUKIN 12; ONCOLYTIC HERPES VIRUS; PHOSPHATE BUFFERED SALINE; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER INHIBITION; CELL DIVISION; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; DEMYELINATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOCAL NEEDLE TRACK DAMAGE; HIND LIMB SCORING SYSTEM; HUMAN; HUMAN CELL; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MOUSE; NERVE FIBER DEGENERATION; NERVE INJURY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; SCIATIC NERVE; SCORING SYSTEM; TUMOR GROWTH; 129 MOUSE; ANIMAL; BRAIN NEOPLASMS; C57BL MOUSE; DISEASE MODEL; DRUG SCREENING; GENE VECTOR; GENETICS; INTRALESIONAL DRUG ADMINISTRATION; NERVE SHEATH NEOPLASMS; NUDE MOUSE; PROCEDURES; SIMPLEXVIRUS; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENETIC VECTORS; INJECTIONS, INTRALESIONAL; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, NUDE; NERVE SHEATH NEOPLASMS; ONCOLYTIC VIROTHERAPY; SIMPLEXVIRUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904341721     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not317     Document Type: Article

References (59)

1. Grobmyer SR, Reith JD, Shahlaee A, et al. Malignant peripheral nerve sheath tumor: Molecular pathogenesis and current management considerations. J Surg Oncol. 2008;97:340-349 (Pubitemid 351358582)
2. Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009;249:1014-1022
3. Kroep JR, Ouali M, Gelderblom H, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: An EORTC soft tissue and bone sarcoma group study. Ann Oncol. 2011;22:207-214
4. Widemann BC. Current status of sporadic and neurofibromatosis type 1-Associated malignant peripheral nerve sheath tumors. Curr Oncol Rep. 2009;11:322-328
5. Kolberg M, Holand M, Agesen TH, et al. Survival meta-Analyses for .1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol. 2013;15: 135-147
6. Porter DE, Prasad V, Foster L, et al. Survival in malignant peripheral nerve sheath tumours: A comparison between sporadic and neurofibromatosis type 1-Associated tumours. Sarcoma. 2009; 2009:Article ID 756395
7. Gottfried ON, Viskochil DH, Couldwell WT. Neurofibromatosis type 1 and tumorigenesis: Molecular mechanisms and therapeutic implications. Neurosurg Focus. 2010;28:E8
8. Upadhyaya M, Kluwe L, Spurlock G, et al. Germline and somatic NF1 gene mutation spectrum in NF1-Associated malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat. 2008;29:74-82
9. Brossier NM, Carroll SL. Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system. Brain Res Bull. 2012; 88:58-71
10. Vogel KS, Klesse LJ, Velasco-Miguel S, et al. Mouse tumor model for neurofibromatosis type 1. Science. 1999;286:2176-2179
11. Cichowski K, Shih TS, Schmitt E, et al. Mouse models of tumor development in neurofibromatosis type 1. Science. 1999;286: 2172-2176 (Pubitemid 129516295)
12. Liu TC, Zhang T, Fukuhara H, et al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res. 2006;12:6791-6799 (Pubitemid 44876849)
13. Liu TC, Zhang T, Fukuhara H, et al. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther. 2006;14:789-797 (Pubitemid 44752718)
14. Clevers H. The cancer stem cell: Premises, promises and challenges. Nat Med. 2011;17:313-319
15. Suva ML, Riggi N, Stehle JC, et al. Identification of cancer stem cells in Ewings sarcoma. Cancer Res. 2009;69:1776-1781
16. Walter D, Satheesha S, Albrecht P, et al. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One. 2011;6:e19506
17. Stratford EW, Castro R,Wennerstrom A, et al. Liposarcoma cells with Aldefluor and CD133 activity have a cancer stem cell potential. Clin Sarcoma Res. 2011;1:8
18. Martins-Neves SR, Lopes AO, do Carmo A, et al. Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. BMC Cancer. 2012;12:139
19. Salerno M, Avnet S, Bonuccelli G, et al. Sphere-forming cell subsets with cancer stem cell properties in human musculoskeletal sarcomas. Int J Oncol. 2013;43:95-102
20. Spyra M, Kluwe L, Hagel C, et al. Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors. PLoS One. 2011;6: E21099
21. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 2002;9:967-978 (Pubitemid 35462560)
22. Todo T. Active immunotherapy: Oncolytic virus therapy using HSV-1. Adv Exp Med Biol. 2012;746:178-186
23. Friedman GK, Pressey JG, Reddy AT, et al. Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther. 2009;17: 1125-1135
24. Kaur B, Chiocca EA, Cripe TP. Oncolytic HSV-1 virotherapy: Clinical experience and opportunities for progress. Curr Pharm Biotechnol. 2012;13:1842-1851
25. Jeyaretna DS, Kuroda T. Recent advances in the development of oncolytic HSV-1 vectors: arming of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction. Curr Opin Mol Ther. 2007;9:447-466 (Pubitemid 47574621)
26. Kaur B, Cripe TP, Chiocca EA. Buy one get one free: Armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther. 2009;9:341-355
27. Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001;98:6396-6401 (Pubitemid 32488248)
28. Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, et al. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Ther. 2007; 14:460-467 (Pubitemid 46588196)
29. Wakimoto H, Kesari S, Farrell CJ, et al. Human glioblastoma-derived cancer stem cells: Establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009;69:3472-3481
30. Li J, Zeng W, Huang Y, et al. Treatment of breast cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Ther. 2012;19: 707-714
31. Cheema TA, Wakimoto H, Fecci PE, et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A. 2013;110:12006-12011
32. Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: Biological properties and clinical application. Clin Cancer Res. 2007;13: 4677-4685 (Pubitemid 47294773)
33. Lippi G, Favaloro EJ. Recombinant platelet factor 4: A therapeutic, anti-neoplastic chimera?. Semin Thromb Hemost. 2010;36:558-569
34. Aidoudi S, Bikfalvi A. Interaction of PF4 (CXCL4) with the vasculature: A role in atherosclerosis and angiogenesis. Thromb Haemost. 2010; 104:941-948
35. Li H, Velasco-Miguel S, Vass WC, et al. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res. 2002;62:4507-4513 (Pubitemid 34827315)
36. Farassati F, Pan W, Yamoutpour F, et al. Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am J Pathol. 2008;173:1861-1872
37. Kanai R, Rabkin SD, Yip S, et al. Oncolytic virus-mediated manipulation of DNA damage responses: Synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst. 2012;104:42-55
38. Kuroda T, Martuza RL, Todo T, et al. Flip-Flop HSV-BAC: Bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biotechnol. 2006;6:40
39. Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57:2006-2021 (Pubitemid 16113778)
40. Byer SJ, Eckert JM, Brossier NM, et al. Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner. Neuro Oncol. 2011;13:28-41
41. Buchstaller J, McKeever PE, Morrison SJ. Tumorigenic cells are common in mouse MPNSTs but their frequency depends upon tumor genotype and assay conditions. Cancer Cell. 2012;21: 240-252
42. Mahller YY, Vaikunth SS, Currier MA, et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther. 2007; 15:279-286 (Pubitemid 46111877)
43. Miller SJ, Rangwala F, Williams J, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res. 2006;66: 2584-2591
44. Wildy P. The progression of herpes simplex virus to the central nervous system of the mouse. J Hyg (Lond). 1967;65:173-192
45. Townsend JJ, Collins PK. Peripheral nervous system demyelination with herpes simplex virus. J Neuropathol Exp Neurol. 1986;45: 419-425 (Pubitemid 16059848)
46. Mashour GA, Moulding HD, Chahlavi A, et al. Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model. Exp Neurol. 2001;169:64-71 (Pubitemid 32424323)
47. Gil Z, Rein A, Brader P, et al. Nerve-sparing therapy with oncolytic herpes virus for cancers with neural invasion. Clin Cancer Res. 2007;13:6479-6485 (Pubitemid 350075038)
48. Sundaresan P, Hunter WD, Martuza RL, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation in mice. J Virol. 2000;74:3832-3841 (Pubitemid 30180325)
49. Markert JM, Cody JJ, Parker JN, et al. Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol. 2012;86:5304-5313
50. Chatterjee D, Katz MH, Rashid A, et al. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2012;36:409-417
51. Kelly K, Brader P, Rein A, et al. Attenuatedmultimutated herpes simplex virus-1 effectively treats prostate carcinomas with neural invasion while preserving nerve function. FASEB J. 2008;22:1839-1848 (Pubitemid 351811461)
52. Mahller YY, Vaikunth SS, Ripberger MC, et al. Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res. 2008;68:1170-1179 (Pubitemid 351272236)
53. Maldonado AR, Klanke C, Jegga AG, et al. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors. J Gene Med. 2010;12:613-623
54. Toda M, Rabkin SD, Kojima H, et al. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-Tumor immunity. Hum Gene Ther. 1999;10:385-393 (Pubitemid 29097317)
55. Miller CG, Fraser NW. Role of the immune response during neuro-Attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res. 2000;60:5714-5722
56. Li H, Dutuor A, Tao L, et al. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res. 2007;13: 316-322 (Pubitemid 46121885)
57. Farrell CJ, Zaupa C, Barnard Z, et al. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res. 2008; 14:7711-7716
58. Fukuhara H, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin Cancer Res. 2005;11:7886-7890 (Pubitemid 41611635)
59. Kolodkin-Gal D, Edden Y, Hartshtark Z, et al. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect. Gene Ther. 2009;16:905-915